Free Trial

Cadrenal Therapeutics (CVKD) Competitors

Cadrenal Therapeutics logo
$19.89 +0.66 (+3.43%)
Closing price 02/21/2025 04:00 PM Eastern
Extended Trading
$19.73 -0.16 (-0.82%)
As of 02/21/2025 07:16 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

CVKD vs. TSVT, BDTX, IVA, CABA, NVCT, RENB, CRBU, CRBP, MIST, and VTYX

Should you be buying Cadrenal Therapeutics stock or one of its competitors? The main competitors of Cadrenal Therapeutics include 2seventy bio (TSVT), Black Diamond Therapeutics (BDTX), Inventiva (IVA), Cabaletta Bio (CABA), Nuvectis Pharma (NVCT), Renovaro (RENB), Caribou Biosciences (CRBU), Corbus Pharmaceuticals (CRBP), Milestone Pharmaceuticals (MIST), and Ventyx Biosciences (VTYX). These companies are all part of the "pharmaceutical products" industry.

Cadrenal Therapeutics vs.

2seventy bio (NASDAQ:TSVT) and Cadrenal Therapeutics (NASDAQ:CVKD) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, analyst recommendations, earnings, risk, profitability, institutional ownership, dividends, valuation and community ranking.

2seventy bio has a beta of 1.74, suggesting that its stock price is 74% more volatile than the S&P 500. Comparatively, Cadrenal Therapeutics has a beta of 1.37, suggesting that its stock price is 37% more volatile than the S&P 500.

2seventy bio received 19 more outperform votes than Cadrenal Therapeutics when rated by MarketBeat users. However, 100.00% of users gave Cadrenal Therapeutics an outperform vote while only 52.08% of users gave 2seventy bio an outperform vote.

CompanyUnderperformOutperform
2seventy bioOutperform Votes
25
52.08%
Underperform Votes
23
47.92%
Cadrenal TherapeuticsOutperform Votes
6
100.00%
Underperform Votes
No Votes

Cadrenal Therapeutics has lower revenue, but higher earnings than 2seventy bio. Cadrenal Therapeutics is trading at a lower price-to-earnings ratio than 2seventy bio, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
2seventy bio$100.39M1.34-$217.57M-$1.86-1.40
Cadrenal TherapeuticsN/AN/A-$8.36M-$6.68-2.98

2seventy bio currently has a consensus price target of $7.20, suggesting a potential upside of 175.86%. Cadrenal Therapeutics has a consensus price target of $32.00, suggesting a potential upside of 60.88%. Given 2seventy bio's higher probable upside, equities analysts clearly believe 2seventy bio is more favorable than Cadrenal Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
2seventy bio
1 Sell rating(s)
2 Hold rating(s)
2 Buy rating(s)
1 Strong Buy rating(s)
2.50
Cadrenal Therapeutics
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00

In the previous week, 2seventy bio had 4 more articles in the media than Cadrenal Therapeutics. MarketBeat recorded 4 mentions for 2seventy bio and 0 mentions for Cadrenal Therapeutics. 2seventy bio's average media sentiment score of 0.15 beat Cadrenal Therapeutics' score of 0.00 indicating that 2seventy bio is being referred to more favorably in the media.

Company Overall Sentiment
2seventy bio Neutral
Cadrenal Therapeutics Neutral

93.9% of 2seventy bio shares are held by institutional investors. Comparatively, 7.9% of Cadrenal Therapeutics shares are held by institutional investors. 7.2% of 2seventy bio shares are held by company insiders. Comparatively, 48.6% of Cadrenal Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Cadrenal Therapeutics has a net margin of 0.00% compared to 2seventy bio's net margin of -207.25%. 2seventy bio's return on equity of -53.65% beat Cadrenal Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
2seventy bio-207.25% -53.65% -23.67%
Cadrenal Therapeutics N/A -142.95%-118.40%

Summary

2seventy bio beats Cadrenal Therapeutics on 12 of the 17 factors compared between the two stocks.

Get Cadrenal Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for CVKD and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

CVKD vs. The Competition

MetricCadrenal TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$35.40M$7.07B$5.81B$9.02B
Dividend YieldN/A2.77%4.77%3.84%
P/E Ratio-2.983.9221.5016.68
Price / SalesN/A314.28453.1985.13
Price / CashN/A67.8343.9637.32
Price / Book2.246.757.654.65
Net Income-$8.36M$138.11M$3.18B$245.69M
7 Day Performance4.25%-2.54%-1.95%-2.67%
1 Month PerformanceN/A-2.00%-0.23%-2.16%
1 Year PerformanceN/A-5.04%16.69%12.90%

Cadrenal Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
CVKD
Cadrenal Therapeutics
2.9025 of 5 stars
$19.89
+3.4%
$32.00
+60.9%
N/A$35.45MN/A-2.984
TSVT
2seventy bio
2.1813 of 5 stars
$2.45
+6.5%
$7.20
+193.9%
-53.2%$126.40M$100.39M-1.32440Analyst Forecast
News Coverage
BDTX
Black Diamond Therapeutics
3.3805 of 5 stars
$2.23
-9.3%
$15.50
+595.1%
-53.7%$126.17MN/A-1.6890Short Interest ↓
Positive News
IVA
Inventiva
2.0097 of 5 stars
$2.37
-2.4%
$13.25
+458.8%
-13.1%$124.43M$18.91M0.00100Analyst Forecast
News Coverage
Gap Up
CABA
Cabaletta Bio
2.2422 of 5 stars
$2.53
-4.5%
$22.71
+797.8%
-90.7%$123.67MN/A-1.1850Analyst Forecast
NVCT
Nuvectis Pharma
2.4047 of 5 stars
$6.33
-5.7%
$21.00
+231.8%
+7.2%$122.30MN/A-5.468
RENB
Renovaro
0.763 of 5 stars
$0.75
+7.5%
N/A-61.1%$119.59MN/A-0.7820Earnings Report
News Coverage
Gap Up
CRBU
Caribou Biosciences
3.1342 of 5 stars
$1.32
-2.2%
$10.33
+682.8%
-80.8%$119.53M$34.48M-0.80100Gap Up
CRBP
Corbus Pharmaceuticals
4.043 of 5 stars
$9.78
-3.6%
$61.38
+527.6%
-69.9%$119.11MN/A-2.0940Analyst Forecast
Gap Down
MIST
Milestone Pharmaceuticals
2.8119 of 5 stars
$2.23
+3.7%
$13.00
+483.0%
+29.1%$118.93M$1M-2.7530
VTYX
Ventyx Biosciences
3.1131 of 5 stars
$1.67
-3.5%
$10.00
+498.8%
-68.1%$118.09MN/A-0.7130Upcoming Earnings

Related Companies and Tools


This page (NASDAQ:CVKD) was last updated on 2/22/2025 by MarketBeat.com Staff
From Our Partners